DOCSLIB.ORG

2020 Tbilisi

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 Tbilisi 2(534) 2020 TBILISI INID CODES FOR IDENTIFICATION OF BIBLIOGRAPHIC DATA INVENTIONS, UTILITY MODELS (54) Title of the invention (10) Number of publication for application, which has been examined (57) Abstract (11) Number of patent and kind of document (60) Number of examined patent document granted by foreign patent office, date from which patent (21) Serial number of application has effect and country code (22) Date of filing of the application (62) Number of the earlier application and in case of divided application, date of filing an (23) Date of exhibition or the date of the earlier filing and the number of application, if any application (24) Date from which patent may have effect (71) Name, surname and address of applicant (country code) (31) Number of priority application (72) Name, surname of inventor (country code) (32) Date of filing of priority application (73) Name, surname and address of patent owner (country code) (33) Code of the country or regional organization allotting priority application number (74) Name, surname of representative or patent attorney (44) Date of publication of application not granted, but examined and number of bulletin (85) Date of commencement of the national phase of International Application (45) Date of publication of registered document (86) Number and date of filing of international application (51) International Patent Classification Index (87) Number and date of publication of international application (94) Calculated date of expiry of the SPC or the duration of the SPC DESIGNS (10) Number of publication for application (51) International Classification for designs (class and subclass of the Locarno (11) Nnumber of patent and kind of document or number of registration Classification) (15) Date of registration/Date of patent renewal (54) Title of the invention (18) Expected expir ation date of patent or registration (55) Reproduction of the design (21) Serial number of application (57) Description of characteristic features of the design including indication of colors (22) Date of filing of the application (58) Date of recording of any kind of amendment in the Register (62) Number of the earlier application, registration and document number and if available the date (23) Date of exhibition or the date of the earlier filing and the number of application, if any of filing an application in case of divided application (24) Date from which patent may have effect (71) Name, surname and address of applicant (country code) (28) Number of designs included in the application (72) Name, surname of creator (country code) (30) Data relating to priority (number of application, date of filing of application, two-letter code (73) Name, surname and address of patent owner (country code) identifying the authority with whom the priority application was made) (31) Number of priority application (74) Name, surname of representative or patent attorney (81) Contracting states concerned (32) Date of filing of priority application II designated contracting states according to the 1960 Act (33) Code of the country or regional organization allotting priority application number III designated contracting states according to the 1999 Act (34) Two-letter code according to WIPO St.3 identifying the authority with which the priority (85) Owner’s permanent address application was made (86) Owner’s nationality (44) Date of publication of design and number of bulletin (the first publication) (87) Owner’s residence (45) Date of publication of design registered by WIPO and number of bulletin (88) State in which the owner has a real and effective industrial or commercial establishment TRADEMARKS (111) _ Number of registration (540) _ Reproduction of Trade Mark (151) _ Date of registration (550) _ Nature and kind of Trade Mark (156) _ Date of the renewal (551) _ Indication to the effect that the mark is a collective mark, a certification mark or a guarantee mark (181) _ Expected expiration date of registration (554) _ Three-dimensional mark (186) _ Reneval expiration date of registration (580) _ Date of recording of any kind changes in respect of applications or registrations (141) _ Data of cancel of duration of the mark (591) _ Information concerning colors claimed (210) _ Serial number of application (731) _ Name and address of the applicant (220) _ Date of filing of the application (732) _ Name and address of the holder of the registration (230) _ Data concerning exhibition (740) _ Name and address of the representative (260) _ Number of application, for which favorable decision of examination about registration has (750) _ Adrees for correspondence been taken (publication number) (770) _ Name and address of the previous applicant or holder in case of change in ownership (310) _ Number of the first application (771) _ Previous name and address of the applicant or holder in case of change in ownership (320) _ Date of filing of the first application (791) _ Name and address of the licensee (330) _ Code, identifying national or regional Office where the first application was made (793) _ Indication of conditions and/or restrictions under the license (Type of license, number of (511) _ International Classification of Goods and Services for the purposes of registration of trade license agreement, data of license, data of validity of license) marks and/or list of goods and/or services classified according thereto (800) _ Certain data relating to the international registration of Trade Marks under the (526) _ Disclaimer Protocol Relating to Madrid Agreement (International registration number (531) _ Description of figurative elements of Trade Marks according to the International (852) _ Partial cancellation of the list of goods and services Classification of the Figurative Elements of Marks (891) _ Date of subsequent designation CODES FOR PUBLICATION IN BULLETIN (21) AP 0000 000000 _ serial number of application for invention INTERNATIONAL PATENT CLASSIFICATION (10) AP 0000 0000 A _ number of published application for invention (first publication) FOR INVENTIONS AND UTILITY MODELS (11) P 0000 0000 B _ number of patent for invention (second publication) (21) API 0000 000000 _ number of application for imported patent SECTION A _ HUMAN NECESSITIES (11) PI 0000 0000 A _ number of imported patent (first publication) SECTION B _ PERFORMING OPERATIONS; TRANSPORTING SECTION C _ CHEMISTRY; METALLURGY (21) AU 0000 000000 _ serial number of application for utility model SECTION D _ TEXTILES; PAPER (10) AU 0000 000 U _ number of published application for utility model (first publication) SECTION E _ FIXED CONSTRUCTIONS (11) U 0000 000 Y _ number of patent for utility model (second publication) SECTION F _ MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING (21) AD 0000 000000 _ serial number of application for design SECTION G _ PHYSICS (10) AD 0000 000 S _ number of published application for design (first publication) SECTION H _ ELECTRICITY (11) D 0000 000 S _ registered design M _ Trade Mark (210) AM 0000 000000 _ Serial number of application; (260) AAM 0000 00000 A _ Publication number of application; (111) M 0000 00000 R _ Number of registration; (111) MMM0000 00000 Rn _ Number of renewals, in which n=1,2,3; (111) M 0000 00000 R(P) _ Number of registration under partial assignment of rights Date format: year, month, day (YY MM DD) LIST OF CODES, IN ALPHABETIC SEQUENCE, AND THE CORRESPONDING (SHORT) NAMES OF STATES, OTHER ENTITIES AND INTERGOVERNMENTAL ORGANIZATIONS (WIPO STANDARD ST.3) AD Andorra for the Arab States of the Gulf (GCC) NE Niger AE United Arab Emirates GD Grenada NG Nigeria AF Afghanistan GG Guernsey NI Nicaragua AG Antigua and Barbuda GH Ghana NL Netherlands AI Anguilla GI Gibraltar NO Norway AL Albania GT Guatemala NP Nepal AM Armenia GW Guinea- Bissau NR Nauru AN Netherlands Antilles GY Guyana NZ New Zealand AO Angola HK The Hong Kong Special Administrative OA African Intellectual Property Organization AP African Regional Intellectual Region of the People’s Republic of China (OAPI) Property Organization (ARIPO) HN Honduras OM Oman AR Argentina HR Croatia PA Panama AT Austria HT Haiti PE Peru AU Australia HU Hungary PG Papua New Guinea AW Aruba IB International Bureau of the World PH Philippines AZ Azerbaijan Intellectual Property Organization (WIPO) PK Pakistan BA Bosnia and Herzegovina ID Indonesia PL Poland BB Barbados IE Ireland PT Portugal BD Bangladesh IL Israel PW Palau BE Belgium IM Isle of Man PY Paraguay BF Burkina Faso IN India QA Qatar BG Bulgaria IQ Iraq QZ Community Plant Variety Office BH Bahrain ID Indonesia (European Community) (CPVO) BI Burundi IE Ireland RO Romania BJ Benin IL Israel RS Serbia BM Bermuda IM Isle of Man RU Russian Federation BN Brunei Darussalam IN India RW Rwanda BO Bolivia IQ Iraq SA Saudi Arabia BR Brazil IR Iran (Islamic Republic of) SB Solomon Islands BS Bahamas IS Iceland SC Seychelles BT Bhutan IT Italy SD Sudan BV Bouvet Island JE Jersey SG Singapore BW Botswana JM Jamaica SH Saint Helena BX Benelux Office for Intellectual JO Jordan SI Slovenia Property (BOIP) JP Japan SK Slovakia BY Belarus KE Kenya SL Sierra Leone BZ Belize KG Kyrgyzstan SM San Marino CA Canada KH Cambodia SN Senegal CD Democratic Republic of the KI Kiribati SO Somalia Congo KM Saint Kitts and Nevis SR Suriname CF Central African Republic KP Democratic People’s Republic of Korea ST Sao Tome and Principe CG Congo KR Republic of Korea SV El Salvador CH Switzerland KW Kuwait SY Syrian Arab Republic CI Cote d’lvoire KY Cayman Islands SZ Swaziland CK Cook Islands KZ Kazakhstan TC Turks and
Load more

Recommended publications
  • Md. Jury Awards $18M to Former Business Partner in Pharma Lawsuit – Maryland Daily Record
    11/26/2018 Md. jury awards $18M to former business partner in pharma lawsuit – Maryland Daily Record Md. jury awards $18M to former business partner in pharma lawsuit By: Anamika Roy Daily Record Legal Affairs Writer November 26, 2018 A jury in a federal lawsuit awarded a Rockville scientist $18 million in a lawsuit against his former business partners. In a lawsuit filed in U.S. District Court in Greenbelt, Claudio De Simone and ExeGi Pharma LLC alleged VSL Pharmaceuticals Inc., Leadiant Biosciences Inc. and Alfasigma USA Inc. tried to make a copy of a drug De Simone created without having access to the proprietary formula and sold a “knock-off” version of the drug. De Simone also alleged the copy product had never been clinically tested, unlike his product, which underwent extensive clinical research, the lawsuit states. After a three-week trial and about 12 hours of deliberations, a jury of seven women and two men found last week that the pharmaceutical companies owe De Simone more than $18 million in damages, including $15 million for false advertising, nearly $1.9 million for unjust enrichment and nearly $1 million for breach of contract, according to online court records. An attorney for De Simone said Monday that the jury was likely swayed in favor of his client because of “the degree of willful misconduct” on the other side. “We proved that they were marketing to the general public, that includes some very sick patients who rely on the product my client invented to manage severe symptoms of gastrointestinal diseases,” said Jeremy W.
    [Show full text]
  • Boletín Fármacos: Agencias Reguladoras Y Políticas
    Boletín Fármacos: Agencias Reguladoras y Políticas Boletín electrónico para fomentar el acceso y el uso adecuado de medicamentos http://www.saludyfarmacos.org/boletin-farmacos/ Publicado por Salud y Fármacos Volumen 23, número 1, Febrero 2020 Boletín Fármacos es un boletín electrónico de la organización Salud y Fármacos que se publica cuatro veces al año: el último día de cada uno de los siguientes meses: febrero, mayo, agosto y noviembre. Editores Núria Homedes Beguer, EE.UU. Antonio Ugalde, EE.UU. Editores Asociados Corina Bontempo Duca de Freitas, Brasil Albin Chaves, Costa Rica Asesor en Regulación Hernán Collado, Costa Rica Ricardo Martínez, Argentina José Ruben de Alcantara Bonfim, Brasil Francisco Debesa García, Cuba Anahí Dresser, México Asesor en Políticas José Humberto Duque, Colombia Marco Barboza, Perú Albert Figueras, España Eduardo Espinoza, El Salvador Sergio Gonorazky, Argentina Federico Tobar, Panamá Alejandro Goyret, Uruguay Eduardo Hernández, México Luis Justo, Argentina Corresponsales Óscar Lanza, Bolivia Rafaela Sierra, Centro América René Leyva, México Steven Orozco Arcila Roberto López Linares, Perú Benito Marchand, Ecuador Gabriela Minaya, Perú Webmaster Bruno Schlemper Junior, Brasil People Walking Xavier Seuba, España Federico Tobar, Panamá Francisco Rossi, Colombia Equipo de Traductores Núria Homedes, EE UU Enrique Muñoz Soler, España Antonio Ugalde, EE.UU. Boletín Fármacos solicita comunicaciones, noticias, y artículos de investigación sobre cualquier tema relacionado con el acceso y uso de medicamentos; incluyendo temas de farmacovigilancia; políticas de medicamentos; ensayos clínicos; ética y medicamentos; dispensación y farmacia; comportamiento de la industria; prácticas recomendables y prácticas cuestionadas de uso y promoción de medicamentos. También publica noticias sobre congresos y talleres que se vayan a celebrar o se hayan celebrado sobre el uso adecuado de medicamentos.
    [Show full text]
  • International Society for Fair Elections and Democracy I S F E D
    International Society for Fair Elections and Democracy I S F E D Monitoring of Post-Election Processes – Staff Changes, Protest Rallies, Legal Proceedings in Local Self-Government Authorities Second Report February 12, 2013 Tbilisi Publishing this report was made possible through the Embassy of Kingdom of the Netherlands to Georgia as well as the United States Agency for International Development (USAID) and with the financial support of the National Democratic Institute (NDI). The views expressed in the report belong solely to the International Society for Fair Elections and Democracy and do not necessarily reflect the views of the Embassy of Kingdom of the Netherlands to Georgia, NDI, USAID or United States Government Contents I. Summary of the Situation II. Monitoring Methodology III. Key Findings of the Monitoring IV. Legal Base V. Detailed Account of the Monitoring 1. The Process of Changing Sakrebulo Chairpersons and Gamgebelis 1.1. Sakrebulo Chairpersons and Gamgebelis Resigning at Their Own Will 1.2. Sakrebulo Chairpersons and Gamgebelis Resigning Amid Protest Rallies 2. Rallies 2.1. Protest Rallies Staged in Municipalities with the Demand for Resignation of Municipal officials 2.2. Physical Clashes and Acts of Violence during Protest Rallies 3. Staff Changes in Self-Governments 4. Developments in Tbilisi Self-Government 5. Governors 6. Instances of Legal Proceedings VI. Conclusion I. Summary of the Situation Although victory of the Georgian Dream coalition in the October 1, 2012 Parliamentary Elections should not have affected distribution of power in local self-governments, the process of replacing municipality officials ensued immediately after the elections were over. Former officials (Gamgebelis, Mayors, Sakrebulo Chairpersons) affiliated with the United National Movement were massively replaced by candidates of the Georgian Dream.
    [Show full text]
  • Eesti Patendileht
    ISSN 2228-3609 EESTI VABARIIK EESTI PATENDILEHT 12/2020 DETSEMBER TALLINN PATENDIAMETI AMETLIK VÄLJAANNE XXVI aastakäik Käesolevas numbris esitatud andmed loetakse avaldatuks 15. detsembril 2020. a Eesti Patendilehte antakse välja patendiseaduse paragrahvi 34 lõike 3 alusel. The Estonian Patent Gazette is the official publication of the Estonian Patent Office published under § 34(3) of the Patents Act of the Republic of Estonia. The data presented in this issue is deemed to be published on 15 December 2020. Patendiameti kvaliteedijuhtimissüsteem vastab ISO 9001:2015 standardile. The Estonian Patent Office implements a Quality Management System according to ISO 9001:2015 standard. Patendiameti The Registry Department registriosakond of the Estonian Patent Office Toompuiestee 7 Toompuiestee 7 15041 Tallinn 15041 Tallinn, ESTONIA Tel 627 7908 Phone +372 627 7908 E-post [email protected] E-mail [email protected] © Patendiamet, 2020 EE PATENDILEHT 12/2020, 15.12.2020 3 SISUKORD CONTENTS Bibliograafiliste andmete identifitseerimise Internationally Agreed Numbers rahvusvahelised numberkoodid (INID-koodid) . 6 for the Identification of Data (INID Codes) . 6 Riikide, teiste ühenduste ja valitsustevaheliste List of Codes of States, Other Entities and organisatsioonide koodid ....................... 7 Intergovernmental Organizations . 7 I. EESTI PATENDID ................... 8 I. ESTONIAN PATENTS ................ 8 BA1A. Avaldatud patenditaotlused ............... - BA1A. Published Patent Applications . - BB2A. Avaldatud rahvusvaheliste taotluste BB2A. Translations
    [Show full text]
  • BOPI 12/2019, Din 30.12.2019
    ROMÂNIA OFICIUL DE STAT PENTRU INVENŢII ŞI MĂRCI BULETINUL OFICIAL DE PROPRIETATE INDUSTRIALĂ Secţiunea CERERI ŞI BREVETE DE INVENŢIE EUROPENE CU EFECTE ÎN ROMÂNIA Nr. 12/2019 Cu ocazia sărbătorilor de iarnă, Editura OSIM® urează cititorilor şi colaboratorilor săi un AN NOU FERICIT, multă sănătate, bucurii şi realizarea tuturor aspiraţiilor pe plan personal şi profesional. La mulţi ani! IUL DE S IC TA F T O P E N T R U I N V I E C N 2020 R T A I I M S I OFICIUL DE STAT PENTRU INVENÞII ªI MÃRCI BUCUREªTI - ROMÂNIA BULETIN OFICIAL DE PROPRIETATE INDUSTRIALÃ SECÞIUNEA CERERI ªI BREVETE DE INVENÞIE EUROPENE CU EFECTE ÎN ROMÂNIA _______________ BOPI 12/2019, din 30.12.2019 REDACÞIA Str. Ion Ghica, nr. 3-5, Bucureºti, România Telefon: 021.306. 08. 00 pânã la 021.306.08.29 Fax: 021 312.38.19 e-mail: office @ osim.ro BULETIN OFICIAL DE PROPRIETATE INDUSTRIALÃ Nr. 12 CUPRINS GENERAL 30 decembrie 2019 Prezentare BOPI ......................................................... 4 Direcþia-Redacþia-Administraþia Coduri normalizate OMPI, utilizate în BOPI . 5 OFICIUL DE STAT PENTRU INVENÞII ªI MÃRCI Str. Ion Ghica, nr. 5, sector 3 telefon: 021 306 08 00 II. BREVETE DE INVENÞIE EUROPENE CU EFECTE ÎN ROMÂNIA . 7 pânã la 021.306.08.29 fax: 021 .312.38.19 e-mail: office @ osim.ro 1. Brevete de invenþie europene pentru care a fost depusã traducerea în http://www.osim.ro limba românã a fasciculului brevetului european, conform art. 6 alin. 2 din BUCUREªTI-ROMÂNIA Legea nr. 611/2002 ................................................. 9 2. Brevete de invenþie europene pentru care a fost depusã traducerea în limba românã a fasciculului brevetului european, conform art.
    [Show full text]
  • The Role of Social Capital in Rural Community Development in Georgia
    საზოგადოების კვლევის ცენტრი Centre for Social Studies Marina Mushkelishvili, Lia Mezvrishvili, Beka Natsvlishvili, Mariam Elizbarashvili The Role of Social Capital in Rural Community Development in Georgia Tbilisi 2012 1 @ Centre for Social Studies This study was conducted with the support of the Academic Swiss Caucasus Net (ASCN). ASCN is a program aimed at promoting the social sciences and humanities in the South Caucasus (primarily Georgia and Armenia). Its different activities have fostered the emergence of a new generation of talented scholars. Promising junior researchers receive support through research projects, capacity-building training and scholarships. The program emphasizes the advancement of individuals who become better integrated in international academic networks, thanks to the ASCN experience. The ASCN program is coordinated and operated by the Interfaculty Institute for Central and Eastern Europe (IICEE) at the University of Fribourg (Switzerland). It was initiated and supported by Gebert Rüf Stiftung. 2 Content Introduction 4 Chapter 1. The Georgian Village – 20 Years of Economic and Political Transformation 6 Chapter 2. Social capital – Theoretical Vision 17 Chapter 3. Village Resources and Forms of Cooperation 33 Chapter 4. Social Capital of Rural Communities 43 Chapter 5. Community-Based Associations: Institutional Analysis 59 Chapter 6. Conclusions and Recommendations for Further Reforms 73 Bibliography 79 Annex 1. Data Used in the Process of Analysis (Frequency Distributions) 84 Annex 2. Sample Villages 95 3 Introduction Notwithstanding – or as a result of – the political and economic changes that have occurred in Georgia during the last twenty years, rural areas of Georgia have undergone substantial economic degradation. High levels of unemployment, poverty, unprotected rights, and the migration of youth underline the problems of village life.
    [Show full text]
  • Second National Action Program to Combat Desertification
    Second National Action Program to Combat Desertification 2014-2022 1 National Action Programme (NAP) to Combat Desertification was elaborated by the initiative of Ministry of Environment and Natural Resources Protection (MOENRP) of Georgia. It was developed in the frames of the project “Alignment of National Action Program and reporting process under UNCCD”. The project was implemented Regional Environmental Centre for Caucasus (REC C). Governmental and Non-governmental Organizations, scientific institutions, international organizations and group of experts were participating in development of second National Action Program to Combat Desertification. In the planning of main concept, identification of thematic components and development of document structure were participating: Ms. Nino Chikovani, Ms. Sophiko Akhobadze, Ms. Ketevan Tsereteli, Mr. Malkhaz Dzneladze. On separate thematic components of the program were working: Advocacy, awareness and education _ Ms. Ekaterine Khvedelidze Policy framework and Capacity Building _ Mr. Malkhaz Dzneladze Science, Technology and Knowledge _ Ms. Nana Bolashvili Resource Mobilization _ Ms. Ketevan Tsereteli Program development process was based on the meetings of stakeholders, and the representatives of Governmental, Non-governmental Organizations, Scientific Institutions were expressing their opinions and proposals. They all were reflected in the main part of the Program and also in planned activities. The stakeholders participating in the meetings: Ministry of Environment and Natural Resources
    [Show full text]
  • Tesi Di Ricerca
    Corso di Dottorato di ricerca in Scienze dell’Antichità ciclo XIX Tesi di Ricerca An attempt at re-defining the Late Bronze/Early Iron Age sequence of the Shida Kartli region of Georgia (Southern Caucasus) on the basis of data from recent excavations. Coordinatore del Dottorato ch. prof. Filippo Carinci Supervisore ch. prof. Elena Rova Dottorando Davit Darejanashvili Matricola 982871 2 Index Introduction Chapter 1 -- Geographical background Chapter 2 - History of Archaeological Research in Georgia. Theoretical Developments, the Influences of Nationalism and Politics in Georgian Archaeology 2.1 General historical background 2.2 Archaeology in Georgia during the period of the Russian empire and of the Soviet Union 2.3 The Soviet Union and the development of Georgian archaeology 2.4 Post-soviet archaeology in Georgia 2.5 Researching the Late Bronze in Georgia. The History and Critic Chapter 3 – The Late Bronze — Early Iron period in Georgia (Shida Kartli): state of the art 3.1 The Late Bronze – Early Iron cultures in the Southern Caucasus (XV-VIII centuries BC) 3.2 A detailed description of the contrasting opinions about cultural occupation 3.3 Periodization and absolute chronologies Chapter 4 – Excavated LB/EIA archaeological sites in East Georgian territory Chapter 5 – Late Bronze-Early Iron age pottery Chapter 6 – Aradetis Orgora 6.1 General description of the site 6.2 The LB/EI levels of the site: the stratigraphy of three of years excavations 6.3 LB/EI pottery from Aradetis Orgora – 6.4 Typology 3 6.5 Pottery sequence Chapter 7 – Discussion
    [Show full text]
  • East-West Highway Corridor Improvement Project
    Document of The World Bank FOR OFFICIAL USE ONLY Public Disclosure Authorized Report No: PAD1221 INTERNATIONAL BANK FOR RECONSTRUCTION AND DEVELOPMENT PROJECT APPRAISAL DOCUMENT ON A PROPOSED LOAN IN THE AMOUNT OF US$140 MILLION Public Disclosure Authorized TO GEORGIA FOR A EAST-WEST HIGHWAY CORRIDOR IMPROVEMENT PROJECT October 19, 2015 Public Disclosure Authorized Global Practice Transport and ICT Europe and Central Asia Public Disclosure Authorized This document has a restricted distribution and may be used by recipients only in the performance of their official duties. Its contents may not otherwise be disclosed without World Bank authorization. CURRENCY EQUIVALENTS (Exchange Rate Effective June 15, 2015) Currency Unit = Georgian Lari (GEL) US1.00 = 2.23 GEL 1.00 GEL = US$0.45 FISCAL YEAR January 1 – December 31 ABBREVIATIONS AND ACRONYMS AADT Average Annual Daily Traffic IFI International Finance Institutions ADB Asian Development Bank IFR Interim Un-audited Financial Reports BOQ Bill of Quantities IPSAS Integrated Public Sector Accounting Software CAS Country Assistance Strategy IRI International Roughness Index CPS Country Partnership Strategy ISA International Standards on Auditing CQS Consultant Qualifications IT Information Technology DA Designated Account ITS Intelligent Transport Systems DC Direct Contracting JICA Japanese International Cooperation Agency EIB European Investment Bank LCS Least-Cost Selection Ministry of Economy and Sustainable EIRR Economic Internal Rate of Return MESD Development EMF Environmental Management
    [Show full text]
  • The Pharma 1000 Top Global Pharmaceutical Company Report
    The Pharma 1000 Top Global Pharmaceutical Company Report September 2020 © 2020. All rights reserved. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. In Europe such services are offered through Torreya Partners (Europe) LLP, which is authorized and regulated by the UK Financial Conduct Authority. 1 Table of Contents The Evolving Global Pharmaceutical Sector 5 The Biotechnology Sector 16 The Branded Pharma Sector 24 The Generic Drug Sector 34 Financial Players in Pharma: Private Equity and Royalty Firms 38 Top Players by Country and Segment 44 The Pharma 1000 List 55 About Torreya and Acknowledgements 96 2 Torreya’s Pharma 1000 Report . Torreya is a globally active investment bank focused on the pharmaceutical sector. We began to track assets, people and companies in the industry with our own database in 2012. In “The Pharma 1000” report, we leverage our database to identify the top 1000 companies by value today. This presentation provides a summary of the key findings of the report. We hope to give you a greater sense of the global scale of the pharmaceutical industry and its extraordinary growth. We also wish to recognize the companies that appear on the Pharma 1000 list for the accomplishment of becoming a top company in one of the world’s most important and challenging Download the Full Report industries. 3 Torreya Pharma 1000 Study Approach . We identified approximately 30,000 pharmaceutical companies in 2012. Our team studied these companies and pulled out the active operating companies in ethical pharmaceuticals which had a tangible basis for valuation.
    [Show full text]
  • ვაზისა და ღვინის კულტურა საქართველოში GRAPE and Wine Culture in Georgia
    მაია მირველაშვილი, დავით მაღრაძე Maia Mirvelashvili, David Maghradze ვაზისა და ღვინის კულტურა საქართველოში GRAPE AND WINE CULTURE IN GEORGIA თბილისი/Tbilisi 2015 1 უაკ 634.8+663.2+39 UDC 634.8+663.2+39 სარჩევი Contents მაია მირველაშვილი, დავით მაღრაძე. Maia Mirvelashvili, David Maghradze, 2015. წინასიტყვაობა Foreword 2015. Grape and wine culture in Georgia წარდგინება Introduction ვაზისა და ღვინის კულტურა საქართველოში. Ed. Liana Beriashvili. თავი 1. საქართველოს მევენახეობა და Chapter 1. Viticulture and winemaking in რედ. ლიანა ბერიაშვილი. Tbilisi. National Wine Agency of Georgia. მეღვინეობა Georgia თბილისი. ღვინის ეროვნული სააგენტო. 220 pages. ill. ქვეყნის გეოგრაფიული მდებარეობა Geographical situation of the country 220 გვ. ილ. 13 თავი 2. ვაზის წარმოშობა, დომესტიკაცია Chapter 2. Origin and domestication და მევენახეობა – მეღვინეობის ისტორია of grapevine, history of viticulture and საქართველოში 17 winemaking in Georgia შულავერის კულტურა Shulaveri culture ნაშრომში სამეცნიერო-პოპულარული ენითაა In the given work the issues, related to the მტკვარ-არაქსის კულტურა Kura (Mtkvari) – Arax culture გადმოცემული ვაზისა და ღვინის კულტურის grape and wine culture in Georgia, are included თრიალეთის კულტურა Trialeti culture საკითხები საქართველოში სხვადასხვა and are described with a scientific - popular გვიანი ბრინჯაო – ადრე რკინის ხანა Late bronze – early iron age დისციპლინის (აგრონომია, ისტორია, language from the point-of-view of different კოლხური კულტურა Colchis არქეოლოგია, ეთნოგრაფია, რელიგია, disciplines like agriculture, history, archeology, ანტიკურ-ელინისტური
    [Show full text]
  • Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients
    POLICY AND PRACTICE REVIEWS published: 31 January 2020 doi: 10.3389/fphar.2019.01664 On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients Ciska Verbaanderd 1,2*, Ilse Rooman 2,3, Lydie Meheus 2 and Isabelle Huys 1 1 Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, 2 Anticancer Fund, Strombeek-Bever, Belgium, 3 Oncology Research Centre, Vrije Universiteit Brussel, Brussels, Belgium Repurposing of medicines has gained a lot of interest from the research community in recent years as it could offer safe, timely, and affordable new treatment options for cancer Edited by: patients with high unmet needs. Increasingly, questions arise on how new uses will be Ileana Mardare, translated into clinical practice, especially in case of marketed medicinal products that are Carol Davila University of Medicine and Pharmacy, out of basic patent or regulatory protection. The aim of this study was to portray the Romania regulatory framework relevant for making repurposed medicines available to cancer Reviewed by: patients in Europe and propose specific policy recommendations to address the Guenka Ivanova Petrova, current regulatory and financial barriers. We outlined two routes relevant to the clinical Medical University, Bulgaria adoption of a repurposed medicine. First, a new indication can be approved, and thus Prince Kasongo Mwila, brought on-label, via the marketing authorization procedures established in European and Potchefstroom Hospital, South Africa national legislation. Such procedures initiate a detailed and independent assessment of fi fi *Correspondence: the quality and the bene t-risk balance of a medicinal product in a speci c indication, Ciska Verbaanderd benefiting both prescribers and patients as it reassures them that the scientific evidence is [email protected] robust.
    [Show full text]